Stone Washington is a PhD student in the Trachtenberg School at George Washington University. Stone is employed as a Research Fellow for the Competitive Enterprise Institute, focusing on economic policy as part of the Center for Advancing Capitalism. Previously, he completed a traineeship with the U.S. Securities and Exchange Commission. He was also a Research Assistant at the Manhattan Institute, serving as an extension from his time in the Collegiate Associate Program. During this time, he worked as a Graduate Teaching Assistant in Clemson’s Department of Political Science and served as a WAC Practicum Fellow for the Pearce Center for Professional Communication. Stone is also a member of the Steamboat Institute’s Emerging Leaders Council.
Stone possesses a Graduate Certificate in Public Administration from Clemson University, a Juris Master from Emory University School of Law and a Bachelor of Arts in History from Clemson University. While studying at Emory Law, Stone was featured in an exclusive JM Student Spotlight, highlighting his most memorable law school experience. He has completed a journalism fellowship at The Daily Caller, is an alumnus of the Young Leader’s Program at The Heritage Foundation, and served as a former student intern/Editor for Decipher Magazine. Some of Stone’s articles can be found at EllisWashingtonReport.com, which often provide a critical analysis of prominent works of classical literature and its correlations to American history and politics. Stone is a member of the Project 21 Black Leadership Network, and has written a number of policy-related op-eds for the Wall Street Journal, The Washington Times, The College Fix, Real Clear Policy, and City Journal. In addition to this, Stone is listed in the Marquis Who’s Who in America and is a member of the Golden Key International Honour Society. Friend him on his Facebook page, also his Twitter handle: @StoneZone47 and Instagram. Email him at stonebone20@att.net.
“The evidence presented by Nasdaq in its rule proposal, contrary to its claims, does not show that board diversity provides better returns for shareholders.” ~Excerpt from a Manhattan Institute led amicus curiae brief in the case of Alliance for Fair Board Recruitment vs. SEC. “We will terminate every diversity, equity, and inclusion program across the […]
“I think that was a bad idea when President Franklin Delano Roosevelt tried to pack the court. If anything would make the court appear more partisan, it would be that. So, I am not at all in favor of that solution. Nine seems to be a good number. It’s been that way for a […]
Successful biotech entrepreneurs recount how a favorable corporate-pharma ecosystem facilitated pathbreaking research that introduced novel medicines “This book will be a useful resource for management students and scholars, biomedical scientists, venture capitalists, and other investors, entrepreneurs, healthcare policymakers, and all others interested in how new medicines come into being, why the process is so […]
“A creative adult is a child who survived.” ~ The MB&F perspective on creativity. “Respected by his peers for the quality of his work and his discoveries, Christophe Claret is writing some of the finest chapters in the history of 21st century watchmaking.” ~ Bold Acclaim of watchmaker Christophe Claret. […]
“Our constitutional structure does not permit unaccountable private actors to wield governmental power. FINRA has only minimal oversight from an independent federal agency. Therefore, it must not issue and enforce rules that have the force and effect of federal law. Additionally, none of FINRA’s board members and hearing officers is appointed by the president […]
“Woke or conscientious capitalism is a direct result of activist investors pressuring public companies to adopt politically charged policies that fail to directly impact the financial performance of a company within a reasonable investment time horizon.” ~ Excerpt from a coalition letter supporting the “Stop Woke Investing Act.” “ESG is the […]
“In Sarbanes-Oxley, Congress employed a phrase: ‘discriminate because of’ that has long been recognized to require a plaintiff to show discriminatory intent. It is this transplanted phrase with its rich soil that decides this case.” ~ Eugene Scalia, former Labor Secretary The SEC’s disregard for its own standard procedures presents a major ethical dilemma […]
“The speed and manner in which the FBI opened and investigated Crossfire Hurricane during the presidential election season based on raw, unanalyzed, and uncorroborated intelligence also reflected a noticeable departure from how it approached prior matters involving possible attempted foreign election interference plans aimed at the Clinton campaign.” ~ Special Counsel John Durham, excerpt […]
“Justice is supposed to be blind, regardless of race religion or Creed. However, here in Manhattan the scales of Justice are weighed down by politics. For the District Attorney, justice isn’t blind, it’s about looking for opportunities to advance a radical political agenda. Rather than enforcing the law, the D.A is using his office to […]
Fifth Circuit’s Ruling against “Nasdaq Board Diversity Rule” Safeguards Meritocracy Over Mediocrity
“The evidence presented by Nasdaq in its rule proposal, contrary to its claims, does not show that board diversity provides better returns for shareholders.” ~Excerpt from a Manhattan Institute led amicus curiae brief in the case of Alliance for Fair Board Recruitment vs. SEC. “We will terminate every diversity, equity, and inclusion program across the […]
The Keep Nine Amendment: A Permanent Solution to Threats of Court-Packing
“I think that was a bad idea when President Franklin Delano Roosevelt tried to pack the court. If anything would make the court appear more partisan, it would be that. So, I am not at all in favor of that solution. Nine seems to be a good number. It’s been that way for a […]
Book Review: The Innovative Efficiency and Competitive Dynamism of Biotechnology
Successful biotech entrepreneurs recount how a favorable corporate-pharma ecosystem facilitated pathbreaking research that introduced novel medicines “This book will be a useful resource for management students and scholars, biomedical scientists, venture capitalists, and other investors, entrepreneurs, healthcare policymakers, and all others interested in how new medicines come into being, why the process is so […]
Recent Comments